CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project explores the use of ionizable lipid nanoparticles to induce immune tolerance rather than immunity. By incorporating antigens in a non-immunogenic way, it aims to broaden the application of these nanoparticles in treating allergies and autoimmune diseases.
The recent success of ionizable lipid nanoparticles (iLNPs) as vehicles for mRNA (mRNA-iLNP) as a safe and highly effective vaccine in the protection against SARS-CoV-2 pushed the lipid nanoparticle technology to the forefront of medicine and launched worldwide interest in their potential as a therapeutic vaccine against numerous pathogens or tumor antigens.
Still, their mode of action remains largely a black box.
One of the most remarkable properties of mRNA-LNPs is that they do not require any…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
